Ischemic stroke after recombinant factor VIIa treatment in acquired hemophilia A patient

Acquired hemophilia is a rare, life-threatening coagulopathy in adults caused by the development of autoantibodies against factor VIII. Bypass agents such as recombinant factor VIIa (rFVIIa) are usually preferred for bleeding control; however, thromboembolic complications may occur. We report here a case that presented with extensive cutaneous and mucosal bleedings due to factor VIII inhibitors and was treated successfully with rFVIIa and steroid therapy, but was complicated with a life-threatening thromboembolic attack during follow-up. Blood Coagul Fibrinolysis 23:69-70 (C) 2011 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.